Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Psoriasis
Interventions: etanercept; Biological
Lead sponsor: Florida Academic Dermatology Centers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Psoriasis
Interventions: Micellar Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Avondale, Arizona • Mesa, Arizona • Phoenix, Arizona + 14 more

Conditions: Psoriasis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: alefacept; Biological
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: San Diego, California • Louisville, Kentucky

Conditions: Arthritis, Psoriatic
Interventions: Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 26
States / cities: Encinitas, California • La Jolla, California • San Diego, California + 23 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Psoriasis
Interventions: SB414 6%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Boise, Idaho • Austin, Texas • College Station, Texas + 1 more

Conditions: Psoriasis
Interventions: DFD06 Cream, Clobetasol Propionate Cream 0.05%; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Glendale, Arizona • Mesa, Arizona • Encino, California + 11 more

Conditions: Psoriasis
Interventions: Artificial intelligence, Human, Standard of Care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Arthritis, Psoriatic, Psoriasis
Interventions: Immune Strength; Behavioral
Lead sponsor: Elaine Husni; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-infectious Uveitis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more

Conditions: Scalp Psoriasis
Interventions: UHE-105, Vehicle; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: San Diego, California • High Point, North Carolina

Conditions: Psoriasis
Interventions: placebo, CT 327; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Psoriatic Arthritis
Interventions: Lutikizumab, Risankizumab, ABBV-701, ABBV-547; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 16 more

Conditions: Psoriasis
Interventions: Follow up from previous treatment with MEDI-507; Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Little Rock, Arkansas • Denver, Colorado • Alpharetta, Georgia + 4 more

Conditions: Psoriasis, Arthritic
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; Network
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: La Jolla, California • Seattle, Washington

Conditions: Psoriasis
Interventions: GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: ARQ-151 cream 0.3%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Mountain Brook, Alabama • Scottsdale, Arizona • Fountain Valley, California + 11 more

Search by objective public record fields.

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

Micellar Paclitaxel to Treat Severe Psoriasis

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

A Clinical Trial of Antiplatelets in Psoriasis

Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Assessing Psoriasis Treatment Outcomes

Anakinra for Inflammatory Pustular Skin Diseases

Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

CT 327 in the Treatment of Psoriasis Vulgaris

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Long-Term Follow-Up Study of Psoriasis Patients

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)